# Kalaris Therapeutics, Inc.: Form 8-K, filed Mar 18, 2025

- Company: [Kalaris Therapeutics, Inc.](/companies/klrs.md) (CIK 1754068)
- Form: 8-K
- Filed: 2025-03-18
- Accepted by EDGAR: Mar 18, 2025, 17:04 ET
- Period: 2025-03-18
- Accession: 0001193125-25-056725
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1754068/000119312525056725/d925335d8k.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1754068/000119312525056725/

## Items reported

- Item 2.01: Completion of an acquisition or disposition
- Item 2.02: Results of operations
- Item 5.01: Change in control
- Item 5.02: Departure or appointment of officers or directors
- Item 5.03: Amendment to articles or bylaws
- Item 5.06: Item not in the standard list
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1754068/000119312525056725/d925335d8k.htm

Filed Mar 18, 2025.
Source: SEC EDGAR, the filing index for accession 0001193125-25-056725. Last ingested by Listed: Nov 11, 2026, 00:15 ET. No prices; not investment advice.
